NCT06189144

Brief Summary

An eczematous reaction is an inflammatory intolerance response of the skin. In acute phase the reaction is characterized by erythema and blistering while in the chronic phase it presents as dryness, itchiness and lichenification. Irritative contact dermatitis describes these patterns of reaction in response to toxicity of chemicals on the skin cells, which trigger inflammation by activation of the innate immune system.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 13, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

January 3, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

January 3, 2024

Status Verified

December 1, 2023

Enrollment Period

1 year

First QC Date

September 13, 2023

Last Update Submit

December 18, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • TEWL measurement with Khazaka probe

    Transepidermal water loss

    through study completion, an average of 1 year

  • hydration measurement with corneometer probe

    corneometer assessed stratum corneum hydration level

    through study completion, an average of 1 year

  • erythema measured with mexameter

    mexameter assessed redness

    through study completion, an average of 1 year

Secondary Outcomes (1)

  • clinical score according to dermatologist scale

    through study completion, an average of 1 year

Study Arms (2)

experimental arm

EXPERIMENTAL

SLS irritation model and Treatment

Other: Emollient cream treatment

placebo comparator

PLACEBO COMPARATOR

SLS irritation model and No Treatment

Other: no treatment

Interventions

Rilastil Difesa Sterile cream

experimental arm

no treatment

placebo comparator

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • healthy volunteers who gave written informed consent

You may not qualify if:

  • · skin cancer
  • skin disease
  • skin damage on measurement sites
  • use of drugs that may cause photosensitivity
  • non-adherence to the trial protocol
  • exposure to artificial and excessive natural ultraviolet (UV) radiation
  • pregnancy and lactation
  • history of vitiligo, melasma and other pigmentation and photosensitivity disorders
  • immunosuppression
  • allergic or irritant reactions to the constituents of the cream

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Medicine

Split, 21000, Croatia

RECRUITING

MeSH Terms

Conditions

Dermatitis, ContactDermatitis, Irritant

Condition Hierarchy (Ancestors)

DermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Eczematous

Study Officials

  • josipa bukic

    University of Split, School of Medicine

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

September 13, 2023

First Posted

January 3, 2024

Study Start

June 1, 2023

Primary Completion

June 1, 2024

Study Completion

June 1, 2024

Last Updated

January 3, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will share

On request

Shared Documents
ICF, CSR
Time Frame
On request
Access Criteria
On request

Locations